ReviewInternational journal of molecular sciences2023

Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data.

Federica Villa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.